Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

被引:11
作者
Jaradat, Sara K. [1 ]
Ayoub, Nehad M. [1 ]
Al Sharie, Ahmed H. [2 ]
Aldaod, Julia M. [1 ]
机构
[1] Jordan Univ Sci & Technol JUST, Fac Pharm, Dept Clin Pharm, POB 3030, Irbid 22110, Jordan
[2] Jordan Univ Sci & Technol JUST, Fac Med, Dept Pathol & Microbiol, Irbid, Jordan
关键词
triple-negative breast cancer; receptor tyrosine kinases; small-molecule inhibitors; EGFR; MET; AXL; GROWTH-FACTOR RECEPTOR; POTENTIAL THERAPEUTIC TARGET; FACTOR-I RECEPTOR; GENE COPY NUMBER; CELL LUNG-CANCER; C-KIT; BIOLOGICAL SUBTYPES; CABOZANTINIB XL184; INHIBITS GROWTH; DOWN-REGULATION;
D O I
10.1177/15330338241234780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) comprises a group of aggressive and heterogeneous breast carcinoma. Chemotherapy is the mainstay for the treatment of triple-negative tumors. Nevertheless, the success of chemotherapeutic treatments is limited by their toxicity and development of acquired resistance leading to therapeutic failure and tumor relapse. Hence, there is an urgent need to explore novel targeted therapies for TNBC. Receptor tyrosine kinases (RTKs) are a family of transmembrane receptors that are key regulators of intracellular signaling pathways controlling cell proliferation, differentiation, survival, and motility. Aberrant activity and/or expression of several types of RTKs have been strongly connected to tumorigenesis. RTKs are frequently overexpressed and/or deregulated in triple-negative breast tumors and are further associated with tumor progression and reduced survival in patients. Therefore, targeting RTKs could be an appealing therapeutic strategy for the treatment of TNBC. This review summarizes the current evidence regarding the antitumor activity of RTK inhibitors in preclinical models of TNBC. The review also provides insights into the clinical trials evaluating the use of RTK inhibitors for the treatment of patients with TNBC.
引用
收藏
页数:20
相关论文
共 183 条
[91]   Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells [J].
Li, Jixia ;
Lin, Bihua ;
Li, Xiangyong ;
Tang, Xudong ;
He, Zhiwei ;
Zhou, Keyuan .
ONCOLOGY REPORTS, 2015, 33 (02) :951-957
[92]   Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders [J].
Lin, Po-Han ;
Tseng, Ling-Ming ;
Lee, Yi-Hsuan ;
Chen, Shou-Tung ;
Yeh, Dah-Cherng ;
Dai, Ming-Shen ;
Liu, Liang-Chih ;
Wang, Ming-Yang ;
Lo, Chiao ;
Chang, Stanley ;
Tan, Kien Thiam ;
Chen, Shu-Jen ;
Kuo, Sung-Hsin ;
Huang, Chiun-Sheng .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (12) :2538-2547
[93]   Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers [J].
Linklater, Erik S. ;
Tovar, Elizabeth A. ;
Essenburg, Curt J. ;
Turner, Lisa ;
Madaj, Zachary ;
Winn, Mary E. ;
Melnik, Marianne K. ;
Korkaya, Hasan ;
Maroun, Christiane R. ;
Christensen, James G. ;
Steensma, Matthew R. ;
Boerner, Julie L. ;
Graveel, Carrie R. .
ONCOTARGET, 2016, 7 (43) :69903-69915
[94]   High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy [J].
Litzenburger, Beate C. ;
Creighton, Chad J. ;
Tsimelzon, Anna ;
Chan, Bonita T. ;
Hilsenbeck, Susan G. ;
Wang, Tao ;
Carboni, Joan M. ;
Gottardis, Marco M. ;
Huang, Fei ;
Chang, Jenny C. ;
Lewis, Michael T. ;
Rimawi, Mothaffar F. ;
Lee, Adrian V. .
CLINICAL CANCER RESEARCH, 2011, 17 (08) :2314-2327
[95]   Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer [J].
Liu, Yi-Rong ;
Jiang, Yi-Zhou ;
Xu, Xiao-En ;
Yu, Ke-Da ;
Jin, Xi ;
Hu, Xin ;
Zuo, Wen-Jia ;
Hao, Shuang ;
Wu, Jiong ;
Liu, Guang-Yu ;
Di, Gen-Hong ;
Li, Da-Qiang ;
He, Xiang-Huo ;
Hu, Wei-Guo ;
Shao, Zhi-Ming .
BREAST CANCER RESEARCH, 2016, 18
[96]   Obesity May Not Induce Dynamic Stability Disadvantage during Overground Walking among Young Adults [J].
Liu, Zhong-Qi ;
Yang, Feng .
PLOS ONE, 2017, 12 (01)
[97]   c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment [J].
Lopez-Mejia, Jose A. ;
Tallabs-Utrilla, Luis F. ;
Salazar-Sojo, Pablo ;
Mantilla-Ollarves, Jessica C. ;
Sanchez-Carballido, Manuel A. ;
Rocha-Zavaleta, Leticia .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
[98]   Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J].
Ma, Fei ;
Li, Qiao ;
Chen, Shanshan ;
Zhu, Wenjie ;
Fan, Ying ;
Wang, Jiayu ;
Luo, Yang ;
Xing, Puyuan ;
Lan, Bo ;
Li, Meiying ;
Yi, Zongbi ;
Cai, Ruigang ;
Yuan, Peng ;
Zhang, Pin ;
Li, Qing ;
Xu, Binghe .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) :3105-+
[99]   Overexpression of the RON gene in human breast carcinoma [J].
Maggiora, P ;
Marchio, S ;
Stella, MC ;
Giai, M ;
Belfiore, A ;
De Bortoli, M ;
Di Renzo, MF ;
Costantino, A ;
Sismondi, P ;
Comoglio, PM .
ONCOGENE, 1998, 16 (22) :2927-2933
[100]   The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance [J].
Maroun, Christiane R. ;
Rowlands, Tracey .
PHARMACOLOGY & THERAPEUTICS, 2014, 142 (03) :316-338